Global Enlonstobart Market Strategic Research Report

Scope of the Report

The global Enlonstobart market size is predicted to grow from US$ 27.88 million in 2025 to US$ 65.03 million in 2032; it is expected to grow at a CAGR of 6.6% from 2026 to 2032.

Enlonstobart is a fully human anti‑PD‑1 monoclonal antibody and belongs to the class of immune checkpoint inhibitor anti‑tumor drugs. It specifically binds to the PD‑1 receptor on the surface of human T cells, blocks its combination with ligands, relieves the tumor‑mediated immune suppression, reactivates the body’s endogenous anti‑tumor immune response, and enhances the ability of immune cells to recognize and kill tumor tissues. With a definite anti‑tumor mechanism and controllable safety profile, this drug is clinically mainly used for the treatment of various advanced solid tumors, providing a novel immunotherapy option for tumor patients.In 2025, global Enlonstobart production reached approximately 335,294 vials.

Enlonstobart, a fully human anti-PD‑1 monoclonal antibody independently developed by CSPC Pharmaceutical Group, is an innovative drug in the field of domestic tumor immunotherapy. Relying on differentiated product characteristics and clear clinical positioning, it has gradually established unique competitive advantages in the PD‑1 inhibitor market. Approved for the second-line treatment of recurrent or metastatic cervical cancer, this drug is recommended by authoritative clinical guidelines, filling the treatment gap for specific patient groups and meeting unmet clinical needs. Endowed with low immunogenicity derived from its fully human structure, optimized safety performance and independent intellectual property rights, Enlonstobart boasts sound market expansion potential. With the continuous advancement of medical insurance access and indication expansion, its market accessibility has been further improved. Amid intensified competition and severe homogenization in the domestic PD‑1 track, it has emerged as a high-potential domestic immunotherapy agent by virtue of precise indication layout and reliable clinical efficacy. In the future, it is expected to further strengthen its market influence and industrial position through exploration of combination therapy and overseas market expansion.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Enlonstobart market?

What factors are driving Enlonstobart market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Enlonstobart market opportunities vary by end market size?

How does Enlonstobart break out by Type, by Application?

This report presents a comprehensive overview of the global Enlonstobart market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100mg（10ml）/ vial
• 240mg（24ml）/ vial

Segment by Combination Therapy

• Combination of Enlorsumab and Gemcitabine
• Combination of Enlorsumab and Bevacizumab

Segment by Route of Administration

• Intravenous Infusion
• Intravenous Drip

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Application

• Recurrent Or Metastatic Cervical Cancer
• Esophageal Squamous Cell Carcinoma
• Advanced Solid Tumors
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Enlonstobart market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Recurrent Or Metastatic Cervical Cancer, Esophageal Squamous Cell Carcinoma, Advanced Solid Tumors evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact